Dr. Anderson on Overcoming Suppressive Signals by Engineering T-cells in Ovarian Cancer

Video

Kristin G. Anderson, PhD, discusses overcoming suppressive signaling by engineering T-cells in ovarian cancer.

Kristin G. Anderson, PhD, postdoctoral research fellow, Fred Hutchinson Cancer Research Center, University of Washington, discusses overcoming suppressive signaling by engineering T-cells in ovarian cancer.

Previous findings published in 2021 showed it is possible for patients to overcome suppressive signals that inhibit the activity of T cells by utilizing fusion receptors that combine an inhibitory receptor with an activating signal, Anderson says. Based on these findings, a fast 4-1BB fusion was developed that showed when combined in T cells with the new T-cell receptor. In a mouse model, T-cells combined with the 4-1BB fusion prolonged survival in the animals better than T cells with the receptor alone, Anderson explains.

The mechanism of the 4-1BB fusion increased persistence in the T cells. However, the T cells still lost function in the same way as T cells that only had the T-cell receptor, Anderson continues. Further research was undertaken to determine how to the T-cells could function better in the immunosuppressive tumor microenvironment, Anderson concludes.

Related Videos
Núria Agustí Garcia, MD
Mikkael A. Sekeres, MD, MS
Benjamin Levy, MD
Alessandra Ferrajoli, MD
Saad Z. Usmani, MD, MBA, FACP, FASCO, chief, Myeloma Service, Memorial Sloan Kettering Cancer Center
Petros Grivas, MD, PhD, professor, Clinical Research Division, Fred Hutchinson Cancer Center; professor, Division of Hematology and Oncology, University of Washington (UW) School of Medicine; clinical director, Genitourinary Cancers Program, UW Medicine
Somedeb Ball, MBBS, assistant professor, medicine, Division of Hematology Oncology, Department of Medicine, Vanderbilt University Medical Center
Phillip J. Koo, MD
Gabriella Smith, MD
Mikkael A. Sekeres, MD, MS